Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity

Future Medicinal Chemistry

Volumn 5, Issue 9, 2013, Pages 1059-1071

  Walton Diaz, Annerleim ^a   Khan, Sahar ^a   Bourboulia, Dimitra ^b   Trepel, Jane B ^a   Neckers, Len ^a   Mollapour, Mehdi ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; AT 13387; BIIB 028; BORTEZOMIB; CELASTROL; GANETESPIB; GELDANAMYCIN; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; KU 135; KW 2478; KW 2487; LUMINESPIB; NOVOBIOCIN; PUH 71; RADICICOL; SERENEX; SNX 2112; SNX 5422; TANESPIMYCIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; APOPTOSIS; BINDING KINETICS; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; COLON CARCINOMA; DEACETYLATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; HISTONE ACETYLATION; HISTONE MODIFICATION; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION;

ACETYLATION; ANIMALS; CELL CYCLE PROTEINS; CHAPERONINS; CYCLOPHILINS; HOMEODOMAIN PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MOLECULAR CHAPERONES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84878710811     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.88     Document Type: Review

References (140)

1. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the Hsp90/Hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 228(2), 111-133 (2003).
2. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18(1), 64-76 (2012).
3. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 3(5), 301-323 (2003).
4. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89(2), 239-250 (1997).
5. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42(2), 260-266 (1999).
6. Richter K, Hendershot LM, Freeman BC. The cellular world according to Hsp90. Nat. Struct. Mol. Biol.14(2), 90-94 (2007).
7. Li J, Soroka J, Buchner J. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochim. Biophys. Acta 1823(3), 624-635 (2012).
8. Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta 1823(3), 648-655 (2012).
9. Johnson JL. Evolution and function of diverse Hsp90 homologs and cochaperone proteins. Biochim. Biophys. Acta 1823(3), 607-613 (2012).
10. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10(8), 537-549 (2010).
11. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5(10), 761-772 (2005).
12. Grad I, Cederroth CR, Walicki J, et al. The molecular chaperone Hsp90alpha is required for meiotic progression of spermatocytes beyond pachytene in the mouse. PLoS ONE 5(12), e15770 (2010).
13. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11(7), 515-528 (2010).
14. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci. 59(10), 1640-1648 (2002).
15. Ali MM, Roe SM, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440(7087), 1013-1017 (2006).
16. Dollins DE, Warren JJ, Immormino RM, Gewirth DT. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell 28(1), 41-56 (2007).
17. Graf C, Stankiewicz M, Kramer G, Mayer MP. Spatially and kinetically resolved changes in the conformational dynamics of the Hsp90 chaperone machine. EMBO J. 28(5), 602-613 (2009).
18. Hessling M, Richter K, Buchner J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 16(3), 287-293 (2009).
19. Mickler M, Hessling M, Ratzke C, Buchner J, Hugel T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nat. Struct. Mol. Biol. 16(3), 281-286 (2009).
20. Neckers L, Mollapour M, Tsutsumi S. The complex dance of the molecular chaperone Hsp90. Trends Biochem. Sci. 34(5), 223-226 (2009).
21. Shiau AK, Harris SF, Southworth DR, Agard DA. Structural analysis of E. coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 127(2), 329-340 (2006).
22. Vaughan CK, Gohlke U, Sobott F, et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23(5), 697-707 (2006).
23. Jackson SE. Hsp90: structure and function. Top. Curr. Chem. 328, 155-240 (2013).
24. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271-294 (2006).
25. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. Pharmacol. (172), 259-277 (2006).
26. Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim. Biophys. Acta 1823(3), 756-766 (2012).
27. Alarcon SV, Mollapour M, Lee MJ, et al. Tumor-intrinsic and tumor-extrinsic factors impacting Hsp90-targeted therapy. Curr. Mol. Med. 12(9), 1125-1141 (2012).
28. Modi S, Stopeck A, Linden H, et al. Hsp90 inhibition is effective in breast cancer: a Phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17(15), 5132-5139 (2011).
29. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (Hsp90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152(4), 367-379 (2011).
30. Roue G, Perez-Galan P, Mozos A, et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 117(4), 1270-1279 (2011).
31. Scaltriti M, Serra V, Normant E, et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol. Cancer Ther. 10(5), 817-824 (2011).
32. Schulte TW, Akinaga S, Soga S, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 3(2), 100-108 (1998).
33. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, Hsp90, by the transformation suppressing agent, radicicol. Oncogene 16(20), 2639-2645 (1998).
34. Jensen MR, Schoepfer J, Radimerski T, et al. NVP-AUY922: a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10(2), R33 (2008).
35. Moser C, Lang SA, Hackl C, et al. Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 32(7), 2551-2561 (2012).
36. Nagengast WB, De Korte MA, Oude Munnink TH, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922. J. Nucl. Med. 51(5), 761-767 (2010).
37. Ishii T, Seike T, Nakashima T, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2(4), e68 (2012).
38. Woodhead AJ, Angove H, Carr MG, et al. Discovery of (2,4-dihydroxy-5- isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl] methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem. 53(16), 5956-5969 (2010).
39. Chiosis G, Timaul MN, Lucas B, et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes HER2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8(3), 289-299 (2001).
40. Wright L, Barril X, Dymock B, et al. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem. Biol. 11(6), 775-785 (2004).
41. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106(20), 8368-8373 (2009).
42. Cheung KM, Matthews TP, James K, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 15(14), 3338-3343 (2005).
43. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68(8), 2850-2860 (2008).
44. Nakashima T, Ishii T, Tagaya H, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin. Cancer Res. 16(10), 2792-2802 (2010).
45. Mccleese JK, Bear MD, Fossey SL, et al. The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer 125(12), 2792-2801 (2009).
46. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275(47), 37181-37186 (2000).
47. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl Cancer Inst. 92(3), 242-248 (2000).
48. Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15(26), 2702-2717 (2008).
49. Conde R, Belak ZR, Nair M, O'Carroll RF, Ovsenek N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochem. Cell Biol. 87(6), 845-851 (2009).
50. Matts RL, Brandt GE, Lu Y, et al. A systematic protocol for the characterization of Hsp90 modulators. Bioorg. Med. Chem. 19(1), 684-692 (2011).
51. Shelton SN, Shawgo ME, Matthews SB, et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 76(6), 1314-1322 (2009).
52. Caplan AJ. What is a co-chaperone? Cell Stress Chaperones 8(2), 105-107 (2003).
53. Abbas-Terki T, Briand PA, Donze O, Picard D. The Hsp90 co-chaperones Cdc37 and Sti1 interact physically and genetically. Biol. Chem. 383(9), 1335-1342 (2002).
54. Chang HC, Nathan DF, Lindquist S. In vivo analysis of the Hsp90 cochaperone Sti1 (p60). Mol. Cell. Biol. 17(1), 318-325 (1997).
55. Richter K, Muschler P, Hainzl O, Reinstein J, Buchner J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle. J. Biol. Chem. 278(12), 10328-10333 (2003).
56. Song Y, Masison DC. Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1). J. Biol. Chem. 280(40), 34178-34185 (2005).
57. Lee P, Shabbir A, Cardozo C, Caplan AJ. Sti1 and Cdc37 can stabilize Hsp90 in chaperone complexes with a protein kinase. Mol. Biol. Cell 15(4), 1785-1792 (2004).
58. Maclean M, Picard D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 8(2), 114-119 (2003).
59. Siligardi G, Panaretou B, Meyer P, et al. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J. Biol. Chem. 277(23), 20151-20159 (2002).
60. Vaughan CK, Mollapour M, Smith JR, et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell. 31(6), 886-895 (2008).
61. Mclaughlin SH, Sobott F, Yao ZP, et al. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 356(3), 746-758 (2006).
62. Picard D. Intracellular dynamics of the Hsp90 co-chaperone p23 is dictated by Hsp90. Exp. Cell. Res. 312(2), 198-204 (2006).
63. Sullivan WP, Owen BA, Toft DO. The influence of ATP and p23 on the conformation of Hsp90. J. Biol. Chem. 277(48), 45942-45948 (2002).
64. Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J. Biol. Chem. 278(19), 17228-17235 (2003).
65. Meyer P, Prodromou C, Liao C, et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 23(3), 511-519 (2004).
66. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone aha1. Mol. Cell. 10(6), 1307-1318 (2002).
67. Johnson JL, Halas A, Flom G. Nucleotide-dependent interaction of Saccharomyces cerevisiae Hsp90 with the cochaperone proteins Sti1, Cpr6, and Sba1. Mol. Cell. Biol. 27(2), 768-776 (2007).
68. Mayr C, Richter K, Lilie H, Buchner J. Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties. J. Biol. Chem. 275(44), 34140-34146 (2000).
69. Catlett MG, Kaplan KB. Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p. J. Biol. Chem. 281(44), 33739-33748 (2006).
70. Caplan AJ, Mandal AK, Theodoraki MA. Molecular chaperones and protein kinase quality control. Trends Cell. Biol. 17(2), 87-92 (2007).
71. Zhang M, Boter M, Li K, et al. Structural and functional coupling of Hsp90-and Sgt1-centred multi-protein complexes. EMBO J. 27(20), 2789-2798 (2008).
72. Millson SH, Nuttall JM, Mollapour M, Piper PW. The Hsp90/Cdc37p chaperone system is a determinant of molybdate resistance in Saccharomyces cerevisiae. Yeast 26(6), 339-347 (2009).
73. Vaughan CK, Piper PW, Pearl LH, Prodromou C. A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic Hsp90s. FEBS J. 276(1), 199-209 (2009).
74. Forafonov F, Toogun OA, Grad I, Suslova E, Freeman BC, Picard D. p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol. Cell. Biol. 28(10), 3446-3456 (2008).
75. Johnson JL, Brown C. Plasticity of the Hsp90 chaperone machine in divergent eukaryotic organisms. Cell Stress Chaperones 14(1), 83-94 (2009).
76. Roe SM, Ali MM, Meyer P, et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116(1), 87-98 (2004).
77. Siligardi G, Hu B, Panaretou B, Piper PW, Pearl LH, Prodromou C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem. 279(50), 51989-51998 (2004).
78. Gray PJ Jr, Stevenson MA, Calderwood SK. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67(24), 11942-11950 (2007).
79. Smith JR, Clarke PA, de Billy E, Workman P. Silencing the cochaperone Cdc37 destabilizes kinase clients and sensitizes cancer cells to Hsp90 inhibitors. Oncogene 28(2), 157-169 (2009).
80. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. J. Biol. Chem. 284(51), 35381-35389 (2009).
81. Bandhakavi S, Mccann RO, Hanna DE, Glover CV. A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J. Biol. Chem. 278(5), 2829-2836 (2003).
82. Miyata Y. Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell. Mol. Life Sci. 66(11-12), 1840-1849 (2009).
83. Shao J, Prince T, Hartson SD, Matts RL. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem. 278(40), 38117-38120 (2003).
84. Xu W, Mollapour M, Prodromou C, et al. Dynamic tyrosine phosphorylation modulates cycling of the Hsp90-P50(Cdc37)-AHA1 chaperone machine. Mol. Cell. 47(3), 434-443 (2012).
85. Retzlaff M, Hagn F, Mitschke L, et al. Asymmetric activation of the Hsp90 dimer by its cochaperone aha1. Mol. Cell 37(3), 344-354 (2010).
86. Wang X, Venable J, Lapointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127(4), 803-815 (2006).
87. Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of Hsp90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 68(4), 1188-1197 (2008).
88. Richter K, Walter S, Buchner J. The co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J Mol Biol 342(5), 1403-1413 (2004).
89. Johnson JL, Toft DO. Binding of p23 and Hsp90 during assembly with the progesterone receptor. Mol. Endocrinol. 9(6), 670-678 (1995).
90. Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin. Oncol. 33(4), 457-465 (2006).
91. Onuoha SC, Coulstock ET, Grossmann JG, Jackson SE. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 379(4), 732-744 (2008).
92. Schmid AB, Lagleder S, Grawert MA, et al. The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J. 31(6), 1506-1517 (2012).
93. Li J, Richter K, Buchner J. Mixed Hsp90-cochaperone complexes are important for the progression of the reaction cycle. Nat. Struct. Mol. Biol.18(1), 61-66 (2011).
94. Piper PW, Panaretou B, Millson SH, et al. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors. Gene 302(1-2), 165-170 (2003).
95. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S. Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol. Cell. Biol. 9(9), 3919-3930 (1989).
96. Millson SH, Vaughan CK, Zhai C, et al. Chaperone ligand-discrimination by the TPR-domain protein Tah1. Biochem. J. 413(2), 261-268 (2008).
97. Prodromou C, Siligardi G, O'Brien R, et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J. 18(3), 754-762 (1999).
98. Zuehlke AD, Johnson JL. Chaperoning the chaperone: a role for the co-chaperone Cpr7 in modulating Hsp90 function in Saccharomyces cerevisiae. Genetics 191(3), 805-814 (2012).
99. Li J, Richter K, Reinstein J, Buchner J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat. Struct. Mol. Biol. 20(3), 326-331 (2013).
100. Dolinski KJ, Cardenas ME, Heitman J. CNS1 encodes an essential p60/Sti1 homolog in Saccharomyces cerevisiae that suppresses cyclophilin 40 mutations and interacts with Hsp90. Mol. Cell. Biol. 18(12), 7344-7352 (1998).
101. Goes FS, Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1. Eur. J. Biochem. 268(8), 2281-2289 (2001).
102. Mollapour M, Tsutsumi S, Donnelly AC, et al. Swe1 Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell. 37(3), 333-343 (2010).
103. Iwai A, Bourboulia D, Mollapour M, et al. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle 11(19), 3649-3655 (2012).
104. Scroggins BT, Neckers L. Post-translational modification of heat shock protein 90: impact on chaperone function. Expert Opin. Drug Discov. 2(10), 1403-1414 (2007).
105. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res. 68(12), 4833-4842 (2008).
106. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112(5), 1886-1893 (2008).
107. Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L. Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2(5), 407-417 (2011).
108. Mimnaugh EG, Worland PJ, Whitesell L, Neckers LM. Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the Hsp90 stress protein and the p60v-src tyrosine kinase. J. Biol. Chem. 270(48), 28654-28659 (1995).
109. Wandinger SK, Suhre MH, Wegele H, Buchner J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J. 25(2), 367-376 (2006).
110. Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 8(13), 2050-2056 (2009).
111. Mollapour M, Tsutsumi S, Truman AW, et al. Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol. Cell 41(6), 672-681 (2011).
112. Prodromou C, Panaretou B, Chohan S, et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J. 19(16), 4383-4392 (2000).
113. Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP, Obermann WM. The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol. Cell. Biol. 26(22), 8385-8395 (2006).
114. Nathan DF, Lindquist S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol. Cell. Biol. 15(7), 3917-3925 (1995).
115. Cunningham CN, Krukenberg KA, Agard DA. Intra-and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J. Biol. Chem. 283(30), 21170-21178 (2008).
116. Mollapour M, Neckers L. Detecting Hsp90 phosphorylation. Methods Mol. Biol. 787, 67-74 (2011).
117. Duval M, Le Boeuf F, Huot J, Gratton JP. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 18(11), 4659-4668 (2007).
118. Mollapour M, Tsutsumi S, Neckers L. Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 9(12), 2310-2316 (2010).
119. Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25(1), 151-159 (2007).
120. Robbins N, Leach MD, Cowen LE. Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance. Cell Rep. 2(4), 878-888 (2012).
121. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94(7), 504-513 (2002).
122. Park JH, Kim SH, Choi MC, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 368(2), 318-322 (2008).
123. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280(29), 26729-26734 (2005).
124. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18(5), 601-607 (2005).
125. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 284(12), 7436-7445 (2009).
126. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB. Regulation of the dynamics of Hsp90 action on the glucocorticoid receptor by acetylation/ deacetylation of the chaperone. J. Biol. Chem. 280(40), 33792-33799 (2005).
127. Ai J, Wang Y, Dar JA, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol. Endocrinol. 23(12), 1963-1972 (2009).
128. Millson SH, Chua CS, Roe SM, et al. Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90. FASEB J. 25(11), 3828-3837 (2011).
129. Millson SH, Prodromou C, Piper PW. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta. Biochem. Pharmacol. 79(11), 1581-1588 (2010).
130. Zurawska A, Urbanski J, Matuliene J, et al. Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. Biochim. Biophys. Acta 1803(5), 575-583 (2010).
131. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425(6956), 407-410 (2003).
132. Armstrong H, Wolmarans A, Mercier R, Mai B, Lapointe P. The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922. PLoS ONE 7(11), e49322 (2012).
133. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 91(22), 1940-1949 (1999).
134. Gaspar N, Sharp SY, Pacey S, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 69(5), 1966-1975 (2009).
135. Benchekroun MN, Schneider E, Safa AR, Townsend AJ, Sinha BK. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. Mol. Pharmacol. 46(4), 677-684 (1994).
136. Mccollum AK, Teneyck CJ, Stensgard B, et al. P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 68(18), 7419-7427 (2008).
137. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 65(22), 10536-10544 (2005).
138. Powers MV, Clarke PA, Workman P. Dual targeting of Hsc70 and Hsp72 inhibits Hsp90 function and induces tumor-specific apoptosis. Cancer Cell 14(3), 250-262 (2008).
139. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem. Res. Toxicol. 19(3), 376-381 (2006).
140. Updated list of Hsp90 clients. www.picard.ch/downloads/downloads.html